EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Machine learning approaches to predict early cardiac immune-related adverse events in patients receiving immune checkpoint inhibitors

Michael Sayer, Peter D Chang, Hirofumi Hamano, Reina Yamamoto, Misako Nagasaka, Ali A Naqvi, Pranav M Patel, Yoshito Zamami, Aya F Ozaki

Supportive Care in Cancer · 2026-08 · 34 (8)

DOI: 10.1007/s00520-026-10984-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Supportive Care in Cancer, online erschienen am 29.07.2026. Verfasst von Michael Sayer und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy & Pharmaceutical Sciences, University of California, Irvine, CA, USA. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Machine Learning, Heart Diseases. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Immune checkpoint inhibitor (ICI)–induced cardiac immune-related adverse events (cardiac irAEs) are rare yet serious complications. Clinical assessment tools to identify at-risk patients would allow for more effective prevention strategies, thus improving clinical outcomes. We constructed various machine learning (ML) models to predict these events among patients receiving ICI therapy.

Methods

A cohort of patients receiving ICI therapy from 2010 to 2023 was identified from the TriNetX database. Cardiac irAEs were defined as the occurrence of relevant diagnosis codes within 90 days of ICI initiation, with corresponding hospital visits. We created ML models to predict these events, including elastic net logistic regression and multiple tree-based approaches (gradient boosted trees and random forest). We evaluated model performance with different performance measures and utilized assigned risk scores to stratify risk of cardiac irAEs into low, medium, and high-risk tiers.

Results

We identified 61,117 patients receiving ICI therapy, with nearly 2% of patients experiencing cardiac irAEs. Model performance on testing data was comparable with all approaches (AUC = 0.71–0.72, balanced accuracy = 65–66%). Each model emphasized distinct features to make classifications, as observed with feature importance and SHAP values. Comparing cardiac irAE rates among assigned risk strata, patients identified as high risk were significantly more likely to experience cardiac irAEs compared to lower tiers.

Conclusion

Our preliminary exploration of ML methods demonstrated the potential for risk assessment tools to predict rare cardiac irAEs in patients receiving ICI therapy. Follow-up studies can implement time series approaches to harness longitudinal data that incorporates real-time labs, new diagnoses, and new therapy, to refine predictions further.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsMachine LearningHeart DiseasesHumansPredictive Learning ModelsFemaleMaleAgedMiddle AgedRisk AssessmentRandom ForestClassification AlgorithmsNeoplasmsBoosting Machine Learning AlgorithmsCohort StudiesLogistic ModelsPrediction AlgorithmsDatabases, Factual

Stichwörter der Autor:innen

Immune checkpoint inhibitorsImmune-related adverse eventsMachine learningMyocarditisPericarditisRisk assessment tools

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • School of Pharmacy & Pharmaceutical Sciences, University of California, Irvine, CA, USA.
  • School of Medicine, Pathology & Laboratory Medicine, University of California, Irvine, CA, USA.
  • Donald Bren School of Information and Computer Sciences, University of California, Irvine, CA, USA.
  • Department of Pharmacy, Medical Development Field, Okayama University, Okayama, Japan.
  • Department of Medicinal Pharmacology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
  • Division of Hematology and Oncology, University of California, Irvine, CA, USA.

Zitieren

APA

Sayer, M., Chang, P. D., Hamano, H., Yamamoto, R., Nagasaka, M., Naqvi, A. A., Patel, P. M., Zamami, Y., & Ozaki, A. F. (2026). Machine learning approaches to predict early cardiac immune-related adverse events in patients receiving immune checkpoint inhibitors. Supportive Care in Cancer, 34(8). https://doi.org/10.1007/s00520-026-10984-5

Vancouver

Sayer M, Chang PD, Hamano H, Yamamoto R, Nagasaka M, Naqvi AA, et al. Machine learning approaches to predict early cardiac immune-related adverse events in patients receiving immune checkpoint inhibitors. Supportive Care in Cancer. 2026;34(8). doi:10.1007/s00520-026-10984-5

BibTeX
@article{Sayer2026,
  author = {Sayer, Michael and Chang, Peter D and Hamano, Hirofumi and Yamamoto, Reina and Nagasaka, Misako and Naqvi, Ali A and Patel, Pranav M and Zamami, Yoshito and Ozaki, Aya F},
  title = {Machine learning approaches to predict early cardiac immune-related adverse events in patients receiving immune checkpoint inhibitors},
  journal = {Supportive Care in Cancer},
  year = {2026},
  volume = {34},
  number = {8},
  doi = {10.1007/s00520-026-10984-5}
}
Kostenlos starten →